Thrivent Financial for Lutherans Has $38.51 Million Stake in Stryker Corporation $SYK

by · The Cerbat Gem

Thrivent Financial for Lutherans grew its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 12.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 97,365 shares of the medical technology company’s stock after buying an additional 10,975 shares during the period. Thrivent Financial for Lutherans’ holdings in Stryker were worth $38,507,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Consolidated Portfolio Review Corp increased its stake in Stryker by 4.2% during the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after acquiring an additional 26 shares during the period. Princeton Global Asset Management LLC grew its holdings in shares of Stryker by 16.9% during the 2nd quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after purchasing an additional 26 shares in the last quarter. Sunflower Bank N.A. increased its position in shares of Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after purchasing an additional 27 shares during the period. Pitti Group Wealth Management LLC raised its stake in shares of Stryker by 3.2% in the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after purchasing an additional 27 shares in the last quarter. Finally, Sachetta LLC lifted its position in Stryker by 58.7% in the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the period. Institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

NYSE:SYK opened at $355.34 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68. The firm has a market cap of $135.89 billion, a PE ratio of 46.69, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The company’s 50-day moving average price is $366.60 and its two-hundred day moving average price is $378.26.

Stryker (NYSE:SYK – Get Free Report) last posted its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a net margin of 12.07% and a return on equity of 24.07%. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s dividend payout ratio (DPR) is currently 44.15%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Rothschild Redb raised shares of Stryker to a “hold” rating in a report on Thursday, September 18th. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday, September 18th. Needham & Company LLC reissued a “buy” rating and issued a $448.00 price target on shares of Stryker in a research report on Friday, November 14th. Royal Bank Of Canada restated an “outperform” rating and set a $435.00 price target on shares of Stryker in a research note on Friday, November 14th. Finally, Barclays upped their price objective on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Twelve analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $431.83.

Check Out Our Latest Report on Stryker

Insider Activity

In related news, CFO Preston Wendell Wells sold 165 shares of Stryker stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $365.88, for a total value of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO William E. Berry, Jr. sold 1,953 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the transaction, the chief accounting officer owned 2,833 shares in the company, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. 5.20% of the stock is owned by corporate insiders.

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Featured Stories

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).